Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

Around the world, the COVID-19 pandemic has presented many difficulties, and acute respiratory distress syndrome (ARDS) has become a major worry.

The antiviral and anti-inflammatory characteristics of methylene blue (MB) have garnered interest for potential medicinal applications.

Who Took Part

The study group was 122 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

A randomized clinical study was carried out on 122 hospitalized patients who had ARDS related to COVID-19.

Patients who met the eligibility requirements were randomized at random to either the control group (CG) (n = 60) or the intervention group (IG) (n = 62).

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

Standard treatments were administered to both groups, with the addition of oral MB to the IG.

Clinical outcomes, including SpO2 levels, CRP levels were assessed on the third and fifth days.

Additionally, at the time of discharge, patients' assessments were made in terms of APACHE II scores, SOFA scores, LDH and CRP levels, SpO2, and respiratory rate in comparison to the day prior to the intervention.

Patients were followed for mortality outcomes at one month and three months after the intervention.

What Was Measured

PubMed files the paper under topics including Methylene Blue, Respiratory Distress Syndrome, COVID-19 Drug Treatment, COVID-19, C-Reactive Protein, Antiviral Agents and Anti-Inflammatory Agents.

Author keywords: ARDS.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 122 patients.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Naunyn-Schmiedeberg's archives of pharmacology), a journal based in Germany.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.